These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34575974)

  • 1. Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?
    Olivera GG; Urtasun A; Sendra L; Aliño SF; Yáñez Y; Segura V; Gargallo P; Berlanga P; Castel V; Cañete A; Herrero MJ
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal cancer: pharmacogenetics support for the correct drug prescription.
    Olivera G; Sendra L; Herrero MJ; Puig C; Aliño SF
    Pharmacogenomics; 2019 Jul; 20(10):741-763. PubMed ID: 31368847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade.
    Alessandrini M; Chaudhry M; Dodgen TM; Pepper MS
    OMICS; 2016 Oct; 20(10):593-603. PubMed ID: 27643672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics: personalizing pediatric heart transplantation.
    Van Driest SL; Webber SA
    Circulation; 2015 Feb; 131(5):503-12. PubMed ID: 25645611
    [No Abstract]   [Full Text] [Related]  

  • 5. Future prospects for pharmacogenetics in the quest for personalized medicine.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2012 Dec; 50(12):13-6. PubMed ID: 23457712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children's Genomic Medicine Consortium.
    Gregornik D; Salyakina D; Brown M; Roiko S; Ramos K
    Pharmacogenomics J; 2021 Feb; 21(1):8-19. PubMed ID: 32843689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variant discovery using next-generation sequencing and its future role in pharmacogenetics.
    Russell LE; Schwarz UI
    Pharmacogenomics; 2020 May; 21(7):471-486. PubMed ID: 32338137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics--how close/far are we to practising individualized medicine for children?
    Sing CW; Cheung CL; Wong IC
    Br J Clin Pharmacol; 2015 Mar; 79(3):419-28. PubMed ID: 25855823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomic phase transition from personalized medicine to patient-centric customized delivery.
    Radhakrishnan A; Kuppusamy G; Ponnusankar S; Shanmukhan NK
    Pharmacogenomics J; 2020 Feb; 20(1):1-18. PubMed ID: 31819163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melatonin and neuroblastoma: a novel therapeutic approach.
    Pourhanifeh MH; Kamali M; Mehrzadi S; Hosseinzadeh A
    Mol Biol Rep; 2021 May; 48(5):4659-4665. PubMed ID: 34061325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program.
    Shuldiner AR; Palmer K; Pakyz RE; Alestock TD; Maloney KA; O'Neill C; Bhatty S; Schub J; Overby CL; Horenstein RB; Pollin TI; Kelemen MD; Beitelshees AL; Robinson SW; Blitzer MG; McArdle PF; Brown L; Jeng LJ; Zhao RY; Ambulos N; Vesely MR
    Am J Med Genet C Semin Med Genet; 2014 Mar; 166C(1):76-84. PubMed ID: 24616408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics in pediatrics: personalized medicine showing eminent promise.
    Mele C; Goldschmidt K
    J Pediatr Nurs; 2014; 29(4):378-82. PubMed ID: 24880100
    [No Abstract]   [Full Text] [Related]  

  • 13. What do we need to transfer pharmacogenetics findings into the clinic?
    Slob EMA; Vijverberg SJH; Pijnenburg MW; Koppelman GH; Maitland-van der Zee AH
    Pharmacogenomics; 2018 May; 19(7):589-592. PubMed ID: 29701121
    [No Abstract]   [Full Text] [Related]  

  • 14. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array.
    Johnson JA; Burkley BM; Langaee TY; Clare-Salzler MJ; Klein TE; Altman RB
    Clin Pharmacol Ther; 2012 Oct; 92(4):437-9. PubMed ID: 22910441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics and outcome with antipsychotic drugs.
    Pouget JG; Shams TA; Tiwari AK; Müller DJ
    Dialogues Clin Neurosci; 2014 Dec; 16(4):555-66. PubMed ID: 25733959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?
    Bellanti F; Kågedal B; Della Pasqua O
    Eur J Clin Pharmacol; 2011 May; 67 Suppl 1(Suppl 1):87-107. PubMed ID: 21287160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics knowledge for personalized medicine.
    Whirl-Carrillo M; McDonagh EM; Hebert JM; Gong L; Sangkuhl K; Thorn CF; Altman RB; Klein TE
    Clin Pharmacol Ther; 2012 Oct; 92(4):414-7. PubMed ID: 22992668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conference scene: pediatric pharmacogenomics and personalized medicine.
    Leeder JS; Lantos J; Spielberg SP
    Pharmacogenomics; 2010 Dec; 11(12):1691-702. PubMed ID: 21142913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients.
    Gota V; Chinnaswamy G; Vora T; Rath S; Yadav A; Gurjar M; Veal G; Kurkure P
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):763-8. PubMed ID: 27541143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine.
    Kotelnikova EA; Pyatnitskiy M; Paleeva A; Kremenetskaya O; Vinogradov D
    Oncotarget; 2016 Aug; 7(32):52493-52516. PubMed ID: 27191992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.